利索-全球专利检索

  1. 登录
  2. 注册

搜索结果

115 条记录 (耗时 0.059 秒)

    ANTIBODIES TO CD40
    14.
    发明申请
    ANTIBODIES TO CD40 审中-公开
    CD40抗体

    公开(公告)号：US20100098694A1

    公开(公告)日：2010-04-22

    申请号：US12576459

    申请日：2009-10-09

    申请人： Vahe Bedian ,  Ronald P. Gladue ,  Jose Corvalan ,  Xiao-Chi Jia ,  Xiao Feng

    发明人： Vahe Bedian ,  Ronald P. Gladue ,  Jose Corvalan ,  Xiao-Chi Jia ,  Xiao Feng

    IPC分类号： A61K39/395 ,  C07K16/00 ,  C12N5/00 ,  C07H21/00 ,  C12N15/63 ,  C12P21/00 ,  A01K67/00 ,  A01H5/00 ,  A61P35/00 ,  A61K31/7052

    CPC分类号： C07K16/2866 ,  A01K2217/05 ,  A61K39/3955 ,  A61K45/06 ,  A61K48/00 ,  A61K2039/505 ,  A61N5/062 ,  A61N5/10 ,  C07K16/2878 ,  C07K16/40 ,  C07K2317/14 ,  C07K2317/21 ,  C07K2317/33 ,  C07K2317/34 ,  C07K2317/56 ,  C07K2317/565 ,  C07K2317/75 ,  C07K2317/92

    摘要： The present invention relates to antibodies and antigen-binding portions thereof that specifically bind to CD40, preferably human CD40, and that function as CD40 agonists. The invention also relates to human anti-CD40 antibodies and antigen-binding portions thereof. The invention also relates to antibodies that are chimeric, bispecific, derivatized, single chain antibodies or portions of fusion proteins. The invention also relates to isolated heavy and light chain immunoglobulins derived from human anti-CD40 antibodies and nucleic acid molecules encoding such immunoglobulins. The present invention also relates to methods of making human anti-CD40 antibodies, compositions comprising these antibodies and methods of using the antibodies and compositions for diagnosis and treatment. The invention also provides gene therapy methods using nucleic acid molecules encoding the heavy and/or light immunoglobulin molecules that comprise the human anti-CD40 antibodies. The invention also relates to transgenic animals comprising nucleic acid molecules of the present invention.

    摘要翻译： 本发明涉及与CD40，优选人CD40特异性结合并且作为CD40激动剂起作用的抗体及其抗原结合部分。 本发明还涉及人抗CD40抗体及其抗原结合部分。 本发明还涉及嵌合，双特异性，衍生的单链抗体或融合蛋白的部分的抗体。 本发明还涉及衍生自人抗CD40抗体的分离的重链和轻链免疫球蛋白和编码这种免疫球蛋白的核酸分子。 本发明还涉及制备人抗CD40抗体的方法，包含这些抗体的组合物和使用抗体和组合物进行诊断和治疗的方法。 本发明还提供使用编码包含人抗-CD40抗体的重和/或轻免疫球蛋白分子的核酸分子的基因治疗方法。 本发明还涉及包含本发明的核酸分子的转基因动物。

    REDUCING THE RISK OF HUMAN ANTI-HUMAN ANTIBODIES THROUGH V GENE MANIPULATION
    15.
    发明申请
    REDUCING THE RISK OF HUMAN ANTI-HUMAN ANTIBODIES THROUGH V GENE MANIPULATION 失效
    通过V基因操作降低人类抗体抗体的风险

    公开(公告)号：US20100028906A1

    公开(公告)日：2010-02-04

    申请号：US12577696

    申请日：2009-10-12

    申请人： Sirid-Aimee Kellermann ,  Larry L. Green ,  Wouter Korver

    发明人： Sirid-Aimee Kellermann ,  Larry L. Green ,  Wouter Korver

    IPC分类号： G01N33/53 ,  A01K67/027

    CPC分类号： G01N33/6854 ,  C07K16/464 ,  C07K2317/21 ,  C07K2317/24 ,  C07K2317/56 ,  G01N33/5088

    摘要： The present embodiments relate to methods of identifying and creating human or humanized antibodies that possess a reduced risk of inducing a Human Anti-Human Antibody (HAHA) response when they are applied to a human host. Other methods are directed to predicting the likelihood of a HAHA response occurring. Methods for screening for anti-HAHA compounds are also included. Methods for determining if various conditions for administering an antibody to a subject enhance or suppress a HAHA response are also included.

    摘要翻译： 本实施方案涉及鉴定和产生人或人源化抗体的方法，所述人或人源化抗体在应用于人类宿主时具有诱导人抗人抗体（HAHA）应答的风险降低。 其他方法用于预测发生HAHA反应的可能性。 还包括用于筛选抗HAHA化合物的方法。 还包括用于确定对受试者施用抗体的各种条件是否增强或抑制HAHA应答的方法。

    Determining the risk of human anti-human antibodies in transgenic mice
    17.
    发明授权
    Determining the risk of human anti-human antibodies in transgenic mice 失效
    确定转基因小鼠中人抗体抗体的风险

    公开(公告)号：US07625549B2

    公开(公告)日：2009-12-01

    申请号：US11136250

    申请日：2005-05-23

    申请人： Sirid-Aimée Kellermann ,  Larry L. Green ,  Wouter Korver

    发明人： Sirid-Aimée Kellermann ,  Larry L. Green ,  Wouter Korver

    IPC分类号： A61K49/00 ,  A01K67/027 ,  A01K67/00

    CPC分类号： G01N33/6854 ,  C07K16/464 ,  C07K2317/21 ,  C07K2317/24 ,  C07K2317/56 ,  G01N33/5088

    摘要： The present embodiments relate to methods of identifying and creating human or humanized antibodies that possess a reduced risk of inducing a Human Anti-Human Antibody (HAHA) response when they are applied to a human host. Other methods are directed to predicting the likelihood of a HAHA response occurring. Methods for screening for anti-HAHA compounds are also included. Methods for determining if various conditions for administering an antibody to a subject enhance or suppress a HAHA response are also included.

    摘要翻译： 本实施方案涉及鉴定和产生人或人源化抗体的方法，所述人或人源化抗体在应用于人类宿主时具有诱导人抗人抗体（HAHA）应答的风险降低。 其他方法用于预测发生HAHA反应的可能性。 还包括用于筛选抗HAHA化合物的方法。 还包括用于确定对受试者施用抗体的各种条件是否增强或抑制HAHA应答的方法。

    Transgenic animals for producing specific isotypes of human antibodies via non-cognate switch regions
    18.
    发明授权
    Transgenic animals for producing specific isotypes of human antibodies via non-cognate switch regions 有权
    用于通过非同源转换区产生人抗体特异性同种型的转基因动物

    公开(公告)号：US07547817B2

    公开(公告)日：2009-06-16

    申请号：US11223359

    申请日：2005-09-09

    申请人： Larry L Green ,  Vladimir E Ivanov ,  Geoffrey C Davis

    发明人： Larry L Green ,  Vladimir E Ivanov ,  Geoffrey C Davis

    IPC分类号： A01K67/00 ,  A01K67/027 ,  C12N15/00 ,  C12P21/00

    CPC分类号： C12N15/8509 ,  A01K67/0275 ,  A01K67/0276 ,  A01K67/0278 ,  A01K2207/15 ,  A01K2217/00 ,  A01K2217/05 ,  A01K2217/072 ,  A01K2217/075 ,  A01K2227/105 ,  A01K2267/01 ,  C07K16/00 ,  C07K16/241 ,  C07K16/244 ,  C07K16/248 ,  C07K16/2896 ,  C07K2317/21 ,  C07K2317/52 ,  C12N5/0606 ,  C12N2510/00 ,  C12N2800/30 ,  C12N2830/00

    摘要： The present invention provides fully human antibodies in a transgenic animal of a desired isotype in response to immunization with any virtually any desired antigen. The human immunoglobulin heavy chain transgene in the foregoing animals comprises a human constant region gene segment comprising exons encoding the desired heavy chain isotype, operably linked to switch segments from a constant region of a different heavy chain isotype, i.e., a non-cognate switch region. Said additional constant region segment comprises a switch region and human constant region coding segment, wherein the constant region coding segment is operably linked to a switch region that it is not normally associated with, i.e., a non-cognate switch region. In the transgenes of the invention, the non-cognate switch region may be a switch region from a different species than the constant region coding segment. The switch region and membrane exons of the invention may comprise a human gamma-2 constant region and the secreted constant region exons are from a human gamma-1 or a human gamma-4 constant region.

    摘要翻译： 本发明在任何实际上任何所需抗原的免疫响应中，在所需同种型的转基因动物中提供完全人抗体。 前述动物中的人免疫球蛋白重链转基因包含人恒定区基因片段，其包含编码所需重链同种型的外显子，其可操作地连接于不同重链同种型的恒定区切换片段，即非同源转换区 。 所述附加恒定区段包括开关区域和人类恒定区域编码区段，其中恒定区域编码段可操作地连接到其通常不与非同源开关区域相关联的开关区域。 在本发明的转基因中，非同源开关区可以是来自与恒定区编码区不同的种的开关区。 本发明的切换区和膜外显子可以包含人γ-2恒定区，分泌的恒定区外显子来自人γ-1或人γ-4恒定区。

    Antibodies to c-Met
    19.
    发明授权
    Antibodies to c-Met 有权
    c-Met的抗体

    公开(公告)号：US07498420B2

    公开(公告)日：2009-03-03

    申请号：US10910901

    申请日：2004-08-03

    申请人： Neil R. Michaud ,  Shama Kajiji ,  Gary Borzillo ,  Vahe Bedian ,  Kevin Coleman ,  Larry L. Green ,  Xiao-Chi Jia

    发明人： Neil R. Michaud ,  Shama Kajiji ,  Gary Borzillo ,  Vahe Bedian ,  Kevin Coleman ,  Larry L. Green ,  Xiao-Chi Jia

    IPC分类号： C07K16/00

    CPC分类号： A61K39/39558 ,  A61K2039/505 ,  C07K16/2863 ,  C07K16/3076 ,  C07K2317/21 ,  C07K2317/73 ,  C07K2317/74 ,  C07K2317/75 ,  C07K2317/76 ,  C07K2317/92

    摘要： The present invention relates to antibodies including human antibodies and antigen-binding portions thereof that specifically bind to c-Met, preferably human c-Met, and that function to inhibit c-Met. The invention also relates to human anti-c-Met antibodies and antigen-binding portions thereof. The invention also relates to antibodies that are chimeric, bispecific, derivatized, single chain antibodies or portions of fusion proteins. The invention also relates to isolated heavy and light chain immunoglobulins derived from human anti-c-Met antibodies and nucleic acid molecules encoding such immunoglobulins. The present invention also relates to methods of making human anti-c-Met antibodies, compositions comprising these antibodies and methods of using the antibodies and compositions for diagnosis and treatment. The invention also provides gene therapy methods using nucleic acid molecules encoding the heavy and/or light immunoglobulin molecules that comprise the human anti-c-Met antibodies. The invention also relates to transgenic animals or plants comprising nucleic acid molecules of the present invention.

    摘要翻译： 本发明涉及特异性结合c-Met，优选人c-Met的人抗体及其抗原结合部分的抗体，其功能是抑制c-Met。 本发明还涉及人抗c-Met抗体及其抗原结合部分。 本发明还涉及嵌合，双特异性，衍生的单链抗体或融合蛋白的部分的抗体。 本发明还涉及衍生自人抗c-Met抗体的分离的重链和轻链免疫球蛋白和编码这种免疫球蛋白的核酸分子。 本发明还涉及制备人抗c-Met抗体的方法，包含这些抗体的组合物和使用该抗体和组合物进行诊断和治疗的方法。 本发明还提供使用编码包含人抗c-Met抗体的重和/或轻免疫球蛋白分子的核酸分子的基因治疗方法。 本发明还涉及包含本发明的核酸分子的转基因动物或植物。